Follow-up study for people who received BRT-DA01
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study is for people with Parkinson’s disease who previously took part in an earlier BRT-DA01 trial and finished it (or stopped it). It mainly checks how participants do over time after that earlier treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received BRT-DA01 in the earlier study (MSK-DA01-101).
- That earlier study must be completed or you must have stopped it.
- You must be willing and able to sign written consent for this follow-up study.
- You must agree to come to scheduled study visits and complete study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study follows patients who previously received IPS101A, an experimental gene therapy treatment for severe Parkinson's disease. Researchers want to check how you're doing over time and gather information about the treatment's long-term effects.
This study follows people with Parkinson’s disease, certain Parkinson-like conditions, and some people at higher risk. It helps researchers learn how these illnesses start and progress, which may lead to better earlier detection and care.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This study follows people with Parkinson’s disease to see how their thinking, behavior, and movement change over time after deep brain stimulation. It may help doctors better understand what to expect from this treatment.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.